Table 4.
NEC AEFI and NPEC diagnosis of suspected AESI, nOPV2 AESI surveillance, March 13 - July 7 2021, Nigeria
| Targeted AESI | NEC AEFI/NPEC diagnosis of AE | N (%) |
|---|---|---|
| Group anaphylaxis | Anaphylaxis | 1(0.5%) |
| Group meningo-encephalitis | Focal encephalitis | 4 (1.8%) |
| Group paralysis | Myelitis/transverse myelitis | 48 (17.6%) |
| Guillain Barre syndrome | 1 (0.9%) | |
| Circulating Vaccine-Derived Polio Virus (cVDVP2) | 1(0.5%) | |
| Vaccine-Associated Paralytic Poliomyelitis | 3 (0.5%) | |
| Traumatic/Injection neuritis | 43 (24.3%) | |
| Monoplegia due to nonspecific viral infection | 40 (20.7%) | |
| Hemiparesis/hemiplegia due to CNS infection | 35 (14.4%) | |
| Electrolyte imbalance | 5 (2.3%) | |
| Others* | AEFI | 40 (16.7%) |
| Total | 221 |
*
Cerebral palsy, malaria, acute diarrhoeal disease, measles, bronchopneumonia, seizure disorder, cellulitis, failure to thrive, protein-energy malnutrition, rickets, sepsis, vaso-occlusive crisis in sickle cell patient, hemorrhagic fever, lower limb trauma, muscular dystrophy, delayed developmental milestone, and spinal cord compression ΩNovel oral polio vaccine type 2 adverse event of special interest